Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
about
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF SurveyReal-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants.Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in DenmarkPharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation.Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.Non-valvular atrial fibrillation: impact of apixaban on patient outcomes.Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.Discovery methods of coagulation-inhibiting drugs.Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban.Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database.Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting.Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.Association Between Use of Antithrombotic Medication and Hematuria-Related Complications.Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more.Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near-Real-Time Monitoring Program in Italy.Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.
P2860
Q33897825-8AD5272A-6BE6-4D6D-A10B-649ABABBB631Q36240734-EFC36C15-EAE9-4D83-B9CA-2238894A00E7Q37562899-8A93E4D3-2C24-4423-917E-8E8BE10D73DEQ37672517-58AA76BE-9172-4A50-B2F7-8A350DE893D9Q38598138-66B01E1B-71AF-48B4-859F-BDDBEC169242Q38600440-AE09EB65-0446-4A23-BE6D-E0B6FEC7E316Q38631121-3866C083-2F35-4E18-B297-ABEB3DBB8A59Q38694936-D57B0A5F-3174-4475-A0C8-2C83799255C3Q38712351-F6F15952-5CCD-4E5C-8C6E-8E602BBBBD4BQ38907884-A2A8F26F-7FEF-471B-8590-3CF60133BE2DQ38972335-736A36D0-2034-416B-A76B-58B9945FDD01Q39129273-C14DB654-7096-45A9-8C5D-9DA7B39801BCQ39456624-854DD428-B1B5-4810-B564-41B2BC7F8F68Q40072744-3D6C441F-2D84-4938-B626-799F85BF1D3DQ40242892-1FC1437C-3C70-4D9C-8CCA-B9E4F94958A7Q42688289-69694294-91FD-4F8E-9E3B-33746D29D962Q45974877-B0735E4E-9824-4E43-97AD-9AF89C981FA2Q46050727-9691FB37-141E-496A-A4EC-9BC9F2DAC446Q46109094-13ECD9CA-FBBF-49BA-81E5-CBA68E49C42EQ47097414-CEE3A8F9-04B2-44E3-A308-A06E6876384AQ47114806-35C4AEC7-8DDE-4F60-A471-CE9D29612BDEQ47135998-9BBFA8BB-4BC7-479E-A3D1-CB13C1C980B6Q47136340-4AC9D8F9-B786-453D-9222-852DE2E3F50CQ47581328-6D2F04C7-C602-4EBD-8646-B3E5C2E85362Q47737710-7216251E-DFCB-4944-9022-017D2A5E6AACQ47776628-24213C20-404C-4666-B671-29ED11DA78DAQ47777774-8D48D891-C453-43DE-A0BC-AFBF875A2171Q47781420-43E781D3-2475-4036-89B0-E96C7312DFE5Q47789803-693E330F-CE05-458D-BF2D-A609C7E3BCEBQ47790924-2D674F0D-DCB7-4CA6-ACF8-BBD3F5ECE554Q48158928-5EE409B5-815D-4892-A87E-21659A268CFBQ49189865-E4080DDE-3CD0-47C4-A81F-EF0C6D4CCEF7Q49428555-853C0265-715E-4538-8359-8F8EC28D7AF2Q49499951-1618D47C-6FAC-45E2-96CF-C15F01FCC32BQ49653415-CB7DB1F3-900A-47D5-A515-C7BC23FF6FD8Q50191220-F864289F-509E-4E73-AFCD-8EAFAEDBD995Q50347059-678D881B-41B9-499E-A3E4-842AE84EE703Q51741687-FC178002-47AB-4955-9759-A2C5325618B2Q52603891-B00F68E3-BBB9-493E-89EF-050BBA927B3AQ55001247-092C85BC-EA33-4C4E-B6ED-1FA1D5BAD53D
P2860
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@en
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@nl
type
label
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@en
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@nl
prefLabel
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@en
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@nl
P2093
P2860
P356
P1476
Effectiveness and Safety of Da ...... nvalvular Atrial Fibrillation.
@en
P2093
Lindsey R Sangaralingham
M Fernanda Bellolio
Neena S Abraham
Nilay D Shah
Peter A Noseworthy
P2860
P356
10.1161/JAHA.116.003725
P577
2016-06-13T00:00:00Z